Myopia

FDA accepts Sydnexis’ NDA for SYD-101 in pediatric myopia

Sydnexis, Inc announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) for SYD-101, a low-dose atropine formulation aimed at slowing the progression of pediatric myopia. The FDA has set a target action date of October 23, 2025, under the Prescription Drug User Fee Act....